Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous low-dose decitabine versus supportive care in elderly patients with myelodysplastic syndrome
2005-002830-36Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of decitabine in myelodysplastic syndrome (MDS) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started Nov 2005; status: completed.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2005-002830-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002830-36.